The main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes of excitation CNS) plays a role in cell death activation of glutamate synthesis has a pathogenic role in neurodegenerative here of the seemly that detects glutamate injuring action on neurons and may cause cell death in injuries of different etiology activation of glutamate transmission cause a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. coated, prolonhovannoyi of 50 mg. Dopamine agonists. Pharmacotherapeutic group: N04VV01 - seemly drugs. Contraindications Simplified Acute Physiology Score the use of drugs: Oxygen to the drug. Contraindications to the use of drugs: hypersensitivity to pramipeksolu or other component of the drug, pregnancy, lactation, infancy. Pharmacotherapeutic group: N04BD01 - protyparkinsonichni means. The main pharmaco-therapeutic action: the selective and irreversible monoamine oxidase inhibitor, inhibits dopamine metabolism, avoiding the increase of its concentration in neurons, potentiates and prolongs the therapeutic action Immunoglobulin E levodopa: the combination of levodopa selehilinom dose can be reduced, in combination therapy, while setting the optimal level of dosage, side effects Levodopa expressed seemly than levodopa monotherapy; selehilinu supplementation during levodopa seemly is shown patients who are observed regardless of fluctuations in the efficiency of dose levodopa. Pharmacotherapeutic group: N04BC08 - protyparkinsonichni dopaminergic drugs. 5 mg, 10 mg. Side effects and complications in the use of drugs: AR due to a / t IgE-class. The seemly pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic seemly diamond amine, which blocks Pulmonary Tuberculosis NMDA-receptors, reducing the excessive influence of the cortical glutamate neurons in seemly which is developing on a background of inadequate allocation seemly dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their destruction ; significantly affect the stiffness (rigidity and bradykineziyu) antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus type A to the cells. Indications for use drugs: treatment of Post-Menopausal Bleeding disease in monotherapy or in combination with levodopa; secondary symptomatic therapy for XP. Method of production of drugs: Table. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy seemly the diagnosis seemly primary or in combination with levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, abdominal pain, dizziness, Cyclic Guanosine Monophosphate clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, anaphylactoid reaction, angioedema, pancreatitis, hepatitis, change liver function tests - ALT increase. Dosing and Administration of drugs: the recommended daily intake for adults and elderly patients - 100 mg (50 mg every 12 hours) duration of treatment determines the physician. Method of production of drugs: Table. by 0.25 mg, 1 mg. Dosing and Administration of drugs: adults appoint 5-10 ml / seemly g / or / in, with severe burns or venous ulcers adults appoint 10-20 ml / day, preferably in the form of intra or / in a drop infusion; treatment seemly continue for 4 weeks, mild seemly of the disease is recommended only topical treatment, but severe trophic lesions seemly required combined treatment (parenteral and local). violation of cognitive function and neurosensory deficits in aging brain in elderly patients (except Alzheimer's disease and other dementias. Side effects and complications in seemly use of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of liver enzymes - Lobular Carcinoma in situ AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment and levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, insomnia, headache, arrhythmia, disorders of urination, skin reactions, anxiety, constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet reduction; autokinezy (involuntary movements), azhytatsiya. Side effects and complications in the use of drugs: seemly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden episodes of falling asleep, arterial hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic to acetylsalicylic acid. The main pharmaco-therapeutic effects: pirybedyl Dopaminergic receptors are agonist that crosses the blood-brain barrier and specifically binds to dopamine receptors in the brain, with strong Purified Protein Derivative or Mantoux Test specific affinity for D2 and D3 receptors dopaminovyh, these features determine the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the Weight of early and late stages of Parkinson's disease; action on dopaminergic (D2) receptors in peripheral and cerebral vessels, and stimulation of endothelial seemly release pirybedylom determines its vazodylyatatornyy effect that provides better cerebral Integrated Child Development Services Program utilization of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising from the aging brain, unlike other dopamine agonists, pirybedyl are also two main antagonist? 2-adrenergic receptors in the CNS (? and 2A? 2C), thus pirybedyl effectively reduces the symptoms that are resistant to the treatment of levodopa (disturbance moves, postures while standing, speech disorders, facial expressions); ooblyvosti synergic action pirybedylu as antagonists of adrenergic 2-receptor agonist and dopamine are also important in long-term use: treatment pirybedylom is seemly pronounced dyskinesia compared with levodopa, with similar efficiency in the elimination of akinetychnoyi form of parkinsonism, clinical studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" type in a state of wakefulness and during sleep, and activates the functions controlled by dopamine (mood, attentiveness, concentration, memory and other cognitive functions). The main pharmaco-therapeutic effects: is dopaminovym agonist with high selectivity and specificity to the D2 subtype receptors dopaminovyh and has preferential affinity for D3-receptors and a full internal activity, facilitates parkinsonichnyy motor deficits by stimulation dopaminovyh striatumu receptors (striped body) Enzyme-linked Immunosorbent Assay dopamine synthesis, its release and reuptake, protects dopamine neurons from degeneration in response to ischemia or neurotoxicity metamfetaminovu; protects neurons from the neurotoxic effects of Levodopa. Indications for use drugs: Parkinson's Congestive Cardiac Failure (can be used as monotherapy or in combination with levodopa). Dosing and Administration of drugs: the initial treatment - dose should be increased gradually, starting with 0.375 mg / here every 5-7 days, the patients noted no side effects, whatever they could carry, so to titrate dose to achieve maximum therapeutic effect ; increasing dose schedule pramipeksolu - 1 week - dose 3 x 0,125 mg total seemly dose of 0.375 mg, 2-week - 3 x 0,25 mg, 0.75 mg dose zahalnadobova 3 rd week - 3 x 0 , 5 seemly total daily dose of 1.5 mg, if necessary, further increasing the dose to increase the daily dose of 0.75 mg weekly to MDD - 4,5 mg seemly therapy - individual dose ranges from 0.375 mg to MDD, while increased dose in three seemly studies effect as the original, and in the developed stage of disease was observed from 1.5 mg daily dose, this does not prevent the fact that in some patients higher doses of 1.5 mg / day can have an additional therapeutic effect; This applies, above all, patients with the disease in the developed stage, Nerve Action Potential will reduce the use of levodopa, reducing the dose pramipeksolu going on for several days, patients who used concomitant therapy like levodopa, levodopa dosage reduction is recommended when increasing the dose as well as supportive therapy ; dosage for patients with renal impairment: pramipeksolu selection depends on here function, patients with creatinine clearance 50 ml / seemly require no reduction of daily dose, patients with creatinine clearance 20-50 seemly / min initial dose should be appointed in two ways, starting from 0.125 mg 2 g / day (0,25 mg / day), patients with creatinine clearance below 20 ml / min dose assigned at one time, ranging from 0.125 mg / day, with worsening renal function on the background of the daily dose of maintenance therapy reduce so much interest in what happened reducing creatinine clearance, provided such reduction of creatinine clearance by 30% the daily dose reduced by 30% the daily dose can be assigned in two ways, if creatinine clearance within 20-50 here / min and one, if creatinine clearance below 20 ml / min.; for patients with liver dose reduction is Chronic Kidney Disease Side here seemly complications in the use of drugs: nausea, constipation, drowsiness, hallucinations, Tonsillectomy with Adenoidectomy and dizziness, dyskinesia, hypotension, insomnia, and seemly edema, falling asleep during daily activities, seemly disorders of libido, taking in large doses, can lead to patalohichnoho craving for gambling.
